Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. The multifront midphase program is designed to determine whether the drug ...
Celgene has expanded its deal with Nimbus Therapeutics to secure an option on an HPK1 inhibitor program. Nimbus will take the drug up to a clinical inflection point, at which time Celgene will choose ...
Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his ...
Celgene and the computational chemistry company Nimbus Therapeutics are teaming up to advance R&D on small molecules that could treat a suite of immunology conditions. One Nimbus program is designing ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host a webcast seminar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results